Flu crisis need not cost lives

October 13, 2004

DESPITE the halving of the US's flu vaccine supply, there could be fewer deaths than normal this winter if people follow official advice, New Scientist's analysis suggests. Last week the UK's Medicines and Healthcare Products Regulatory Agency suspended the licence of a factory in Liverpool owned by Chiron Vaccines. The suspension followed the discovery in August of the bacterium Serratia in some batches of flu vaccine. The UK, which was relying on Chiron for only 10 per cent of its supply, has been able to make up the shortfall, and the rest of Europe is mostly unaffected. But the US has been left with a huge deficit. The US, which vaccinates a larger proportion of its population than any other country but Canada, had ordered a record 100 million doses this year.

"We've gone from 20 million doses a year in the early 1990s to 87 million last year," says Bruce Gellin, head of the National Vaccine Program at the US Department of Health. At the start of October, health authorities were urging as many people as possible to get a flu shot. Now the US finds itself with just 56 million doses, roughly half as many as expected. As the news hit the headlines, some Americans queued for hours for flu vaccinations, while Congress held hearings and accusations of mismanagement began to fly. But even such a severe shortage will not necessarily mean more deaths. Two-thirds of the US's supply of flu vaccine usually goes to adults between 18 and 65. Yet 90 per cent of deaths from flu occur in those over 65 years old. In the US, there are around 35 million people over 65. Moreover, in 2002, the most recent year for which figures are available, only 24 million of them got a flu shot. That means the US could vaccinate just as many elderly people as in 2002 and still have 30 million doses of vaccine left over for the other groups for whom vaccinations are officially recommended: people with diseases such as asthma and, for the first time this year, some 10 million children under 2.

The Centers for Disease Control (CDC) is now urging healthy people under 65 not to get vaccinated, to ensure what vaccine there is goes to those most at risk. The impact on flu deaths this year will depend on how closely that advice is followed. Many clinics are turning away healthy adults, as the CDC recommends, while the elderly rush to get their shots amid all the publicity. In fact, if more elderly people than usual get vaccinated as a result, there could actually be fewer flu deaths this winter. A lot will depend on how virulent this season's flu strain turns out to be. The yearly death toll in the US varies from 17,000 to 51,000 depending on severity. The problems with flu vaccine production this year are symptomatic of a wider ailment in the industry stemming from high production costs, static markets and low prices. Last December the US National Vaccine Advisory Committee recommended government purchasing guarantees and other means to ensure that more companies enter the vaccine market. At the time "significant, unprecedented and unanticipated" shortages, which had begun in 2000, were affecting 8 of the 11 routine childhood vaccinations. "The vaccine industry will change," says Jaap Goudsmit, chief scientific officer of Crucell, a Dutch biotech firm that is making a new-generation flu vaccine with Aventis. "This sort of thing just can't continue."
Author: Debora MacKenzie

This article appears in New Scientist issue: 16 October 2004


"These articles are posted on this site to give advance access to other authorised media who may wish to quote extracts as part of fair dealing with this copyrighted material. Full attribution is required, and if publishing online a link to www.newscientist.com is also required. Advance permission is required before any and every reproduction of each article in full - please contact celia.thomas@rbi.co.uk. Please note that all material is copyright of Reed Business Information Limited and we reserve the right to take such action as we consider appropriate to protect such copyright."

New Scientist

Related Flu Vaccine Articles from Brightsurf:

A step toward a universal flu vaccine
Researchers at MIT and the Ragon Institute of MIT, MGH, and Harvard are now working on strategies for designing a universal flu vaccine that could work against any flu strain.

Study provides insight on how to build a better flu vaccine
Repeated exposure to influenza viruses may undermine the effectiveness of the annual flu vaccine.

Flu vaccine could protect against serious heart and stroke complications
The rate of seasonal flu vaccinations among people over age 50 and nursing home residents is extremely low, and those who do get the flu vaccine can significantly lower their risk of heart attack, TIA (transient ischemic attack), death and cardiac arrest.

Study suggests universal flu vaccine may be more challenging than expected
Some common strains of influenza have the potential to mutate to evade broad-acting antibodies that could be elicited by a universal flu vaccine, according to a study led by scientists at Scripps Research.

'Dirty' mice could help make a more effective flu vaccine
Studying mice that have been exposed to other illnesses could help make vaccine development processes more reflective of real-world conditions and lead to better vaccines, according to a new study.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

Flu vaccine is safe for hospitalized patients
Hospitalized patients who received the flu vaccine had no increased risk of outpatient visits or hospital readmission within seven days of discharge, according to a Kaiser Permanente study published today in Mayo Clinic Proceedings.

Close flu vaccine supply gaps to ease flu seasons, make pandemics less deadly
Gaps in the logic of how we restock flu vaccines may be costing hundreds of lives, or more.

Near-infrared spectroscopy could improve flu vaccine manufacturing
Recent research outlines how near-infrared spectroscopy could be used to make cell-culture-based flu vaccine manufacturing faster and more efficient.

An effective adjuvanted intradermal flu vaccine for humans
An intradermal vaccine equipped with an immune response-boosting adjuvant protected ferrets and humans against one of the more lethal strains of pandemic flu, researchers report.

Read More: Flu Vaccine News and Flu Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.